1. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy.
J Neurol Neurosurg Psychiatry 1969;32:28-34.
2. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome).
J Neurol Sci 1989;94:79-100.
3. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy.
Neurology 2008;71:670-676.
4. Ozawa T, Paviour D, Quinn NP, Josephs KA, Sangha H, Kilford L, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations.
Brain 2004;127:2657-2671.
5. Ozawa T, Tada M, Kakita A, Onodera O, Tada M, Ishihara T, et al. The phenotype spectrum of Japanese multiple system atrophy.
J Neurol Neurosurg Psychiatry 2010;81:1253-1255.
6. Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies.
Acta Neuropathol 2011;122:187-204.
7. Lee JH, Song SK, Kim SK, Kim TS, Lee PH. An autopsy case of multiple system atrophy. J Korean Neurol Assoc 2010;28:56-58.
8. Jellinger KA, Seppi K, Wenning GK. Grading of neuropathology in multiple system atrophy: proposal for a novel scale.
Mov Disord 2005;20 Suppl 12:S29-S36.
9. Trojanowski JQ, Revesz T; Neuropathology Working Group on MSA. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy.
Neuropathol Appl Neurobiol 2007;33:615-620.
10. Jellinger KA. Multiple system atrophy: an oligodendroglioneural synucleinopathy1.
J Alzheimers Dis 2018;62:1141-1179.
11. Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, et al. The natural history of multiple system atrophy: a prospective European cohort study.
Lancet Neurol 2013;12:264-274.
12. Wüllner U, Schmitt I, Kammal M, Kretzschmar HA, Neumann M. Definite multiple system atrophy in a German family.
J Neurol Neurosurg Psychiatry 2009;80:449-450.
13. Wakabayashi K, Mori F, Nishie M, Oyama Y, Kurihara A, Yoshimoto M, et al. An autopsy case of early ("minimal change") olivopontocerebellar atrophy (multiple system atrophy-cerebellar).
Acta Neuropathol 2005;110:185-190.
14. Wenning GK, Jellinger KA. The role of alpha-synuclein in the pathogenesis of multiple system atrophy.
Acta Neuropathol 2005;109:129-140.
15. Koga S, Parks A, Uitti RJ, van Gerpen JA, Cheshire WP, Wszolek ZK, et al. Profile of cognitive impairment and underlying pathology in multiple system atrophy.
Mov Disord 2017;32:405-413.
16. Koga S, Dickson DW. Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy.
J Neurol Neurosurg Psychiatry 2018;89:175-184.
17. Yabe I, Soma H, Takei A, Fujiki N, Yanagihara T, Sasaki H. MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA.
J Neurol Sci 2006;249:115-121.
18. Gilman S, May SJ, Shults CW, Tanner CM, Kukull W, Lee VM, et al. The North American Multiple System Atrophy Study Group.
J Neural Transm (Vienna) 2005;112:1687-1694.
19. Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients.
Brain 2002;125:1070-1083.